The sarcoma drugs market size has grown strongly in recent years. It will grow from $1.37 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to healthcare infrastructure, treatment guidelines, patient advocacy groups, improved diagnosis methods, increased disease awareness.
The sarcoma drugs market size is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to demand for novel therapies, healthcare investment, precision medicine, clinical trials and discoveries, research and development. Major trends in the forecast period include immunotherapy advancements, combination therapies, early diagnosis initiatives, biomarker research, patient-centric approach.
The escalating incidence of soft tissue sarcoma is expected to drive the growth of the sarcoma drugs market. Soft tissue sarcoma, a form of cancer originating in the body's soft tissues such as muscles, fat, tendons, lymph, and nerves, is effectively addressed by sarcoma drugs in the healthcare industry. These drugs play a crucial role in treating both bone and soft tissue sarcoma by targeting and disrupting the growth of cancer cells. As reported by the American Cancer Society in January 2023, approximately 13,400 new cases of soft tissue sarcomas are anticipated to be diagnosed in the United States, with an estimated 5,140 deaths attributed to this form of cancer in the same year. Consequently, the increasing prevalence of soft tissue sarcoma is a significant factor propelling the growth of the sarcoma drugs market.
The growing demand for chemotherapy is poised to contribute to the expansion of the sarcoma drugs market. Chemotherapy, a medical intervention involving the use of drugs to kill or inhibit the growth of rapidly dividing cancer cells, finds extensive application in the treatment of sarcoma. Sarcoma drugs utilized in chemotherapy play diverse roles, including tumor reduction, adjuvant treatment, metastasis control, combination therapy, palliative care, risk reduction of recurrence, and enhancement of survival rates. A report from Healthcare IT News in February 2022, citing the Union for International Cancer Control (UICC), predicted a rise in the demand for cancer chemotherapy from 10 million to 15 million by 2040. This surge in demand underscores the increasing reliance on chemotherapy, thereby driving the growth of the sarcoma drugs market.
Key players in the sarcoma drugs market are prioritizing the development of innovative oral medications to improve patient adherence and treatment outcomes. Oral medications are those administered by mouth in forms such as tablets, capsules, or liquid solutions. They are absorbed through the digestive system, offering a convenient and non-invasive way to deliver treatment. For example, in April 2024, Novugen Pharma LLC, a pharmaceutical company based in the U.S., introduced 200 mg pazopanib tablets as a generic alternative to Votrient. This product, which has been approved by the US FDA for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS), underscores Novugen's expertise in complex anticancer formulations. Its launch is expected to improve patient access to effective therapies, significantly influencing the sarcoma drug market by enhancing competition in a previously limited landscape.
Major companies in the sarcoma drugs market are strategically focusing on obtaining product approvals to drive market revenues. Genentech Inc., a US-based biotechnology company, received FDA approval in December 2022 for tecentriq (atezolizumab), a monoclonal antibody. Tecentriq is indicated for the treatment of adult patients with advanced alveolar soft part sarcoma (ASPS), marking the first-ever approved treatment for this uncommon soft tissue sarcoma. The medication targets the PD-1/PD-L1 pathway, blocking immune system suppression and offering a promising therapeutic option for individuals diagnosed with ASPS.
In March 2023, Pfizer Inc., a prominent US-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. This strategic move positions Pfizer Inc. as a leader in cancer care and doubles the size of its oncology portfolio. Seagen Inc., a biotechnology company, is known for its focus on developing new cancer therapies. The acquisition underscores Pfizer's commitment to advancing its capabilities in the oncology space through strategic partnerships and expansion of its product offerings.
Major companies operating in the sarcoma drugs market include Amgen Inc., Bayer AG, Eisai Co. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., AgonOX Inc., Daiichi Sankyo Company Limited, Merck & Co. Inc., AbbVie Inc., Amneal Pharmaceuticals LLC, Pharma Mar SA, Bristol-Myers Squibb Company, Fresenius Kabi AG, Ipsen SA, Radiopharm Theranostics, Akeso Biopharma, AstraZeneca plc, BeiGene Ltd., Bausch Health Companies Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Teva Pharmaceuticals Industries Ltd., Monopar Therapeutics Inc., Incyte Corporation, Sanofi SA, Takeda Pharmaceutical Company Limited, Roche Holding AG.
North America was the largest region in the sarcoma drugs market in 2024. The regions covered in the sarcoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Sarcoma drugs are pharmaceuticals designed for the treatment of sarcoma, a type of cancer that originates in connective tissues such as fat, muscle, blood vessels, nerves, and bones. These drugs are specifically formulated to target abnormal cells, either by directly inducing their death or by inhibiting their growth and multiplication.
The primary treatment modalities for sarcoma drugs include chemotherapy and targeted therapy. Chemotherapy, a widely employed cancer treatment, utilizes drugs to combat cancer cells. The range of disease indications for sarcoma drugs encompasses malignant bone tumors and soft tissue sarcoma, with distribution facilitated through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other relevant outlets.
The sarcoma drugs market research report is one of a series of new reports that provides sarcoma drugs market statistics, including sarcoma drugs industry global market size, regional shares, competitors with a sarcoma drugs market share, detailed sarcoma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoma drugs industry. This sarcoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sarcoma drug market consists of sales of atezolizumab, cosmegen, dactinomycin, doxorubicin hydrochloride, eribulin mesylate, fyarro, and gleevec. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The sarcoma drugs market size is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to demand for novel therapies, healthcare investment, precision medicine, clinical trials and discoveries, research and development. Major trends in the forecast period include immunotherapy advancements, combination therapies, early diagnosis initiatives, biomarker research, patient-centric approach.
The escalating incidence of soft tissue sarcoma is expected to drive the growth of the sarcoma drugs market. Soft tissue sarcoma, a form of cancer originating in the body's soft tissues such as muscles, fat, tendons, lymph, and nerves, is effectively addressed by sarcoma drugs in the healthcare industry. These drugs play a crucial role in treating both bone and soft tissue sarcoma by targeting and disrupting the growth of cancer cells. As reported by the American Cancer Society in January 2023, approximately 13,400 new cases of soft tissue sarcomas are anticipated to be diagnosed in the United States, with an estimated 5,140 deaths attributed to this form of cancer in the same year. Consequently, the increasing prevalence of soft tissue sarcoma is a significant factor propelling the growth of the sarcoma drugs market.
The growing demand for chemotherapy is poised to contribute to the expansion of the sarcoma drugs market. Chemotherapy, a medical intervention involving the use of drugs to kill or inhibit the growth of rapidly dividing cancer cells, finds extensive application in the treatment of sarcoma. Sarcoma drugs utilized in chemotherapy play diverse roles, including tumor reduction, adjuvant treatment, metastasis control, combination therapy, palliative care, risk reduction of recurrence, and enhancement of survival rates. A report from Healthcare IT News in February 2022, citing the Union for International Cancer Control (UICC), predicted a rise in the demand for cancer chemotherapy from 10 million to 15 million by 2040. This surge in demand underscores the increasing reliance on chemotherapy, thereby driving the growth of the sarcoma drugs market.
Key players in the sarcoma drugs market are prioritizing the development of innovative oral medications to improve patient adherence and treatment outcomes. Oral medications are those administered by mouth in forms such as tablets, capsules, or liquid solutions. They are absorbed through the digestive system, offering a convenient and non-invasive way to deliver treatment. For example, in April 2024, Novugen Pharma LLC, a pharmaceutical company based in the U.S., introduced 200 mg pazopanib tablets as a generic alternative to Votrient. This product, which has been approved by the US FDA for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS), underscores Novugen's expertise in complex anticancer formulations. Its launch is expected to improve patient access to effective therapies, significantly influencing the sarcoma drug market by enhancing competition in a previously limited landscape.
Major companies in the sarcoma drugs market are strategically focusing on obtaining product approvals to drive market revenues. Genentech Inc., a US-based biotechnology company, received FDA approval in December 2022 for tecentriq (atezolizumab), a monoclonal antibody. Tecentriq is indicated for the treatment of adult patients with advanced alveolar soft part sarcoma (ASPS), marking the first-ever approved treatment for this uncommon soft tissue sarcoma. The medication targets the PD-1/PD-L1 pathway, blocking immune system suppression and offering a promising therapeutic option for individuals diagnosed with ASPS.
In March 2023, Pfizer Inc., a prominent US-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. This strategic move positions Pfizer Inc. as a leader in cancer care and doubles the size of its oncology portfolio. Seagen Inc., a biotechnology company, is known for its focus on developing new cancer therapies. The acquisition underscores Pfizer's commitment to advancing its capabilities in the oncology space through strategic partnerships and expansion of its product offerings.
Major companies operating in the sarcoma drugs market include Amgen Inc., Bayer AG, Eisai Co. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., AgonOX Inc., Daiichi Sankyo Company Limited, Merck & Co. Inc., AbbVie Inc., Amneal Pharmaceuticals LLC, Pharma Mar SA, Bristol-Myers Squibb Company, Fresenius Kabi AG, Ipsen SA, Radiopharm Theranostics, Akeso Biopharma, AstraZeneca plc, BeiGene Ltd., Bausch Health Companies Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Teva Pharmaceuticals Industries Ltd., Monopar Therapeutics Inc., Incyte Corporation, Sanofi SA, Takeda Pharmaceutical Company Limited, Roche Holding AG.
North America was the largest region in the sarcoma drugs market in 2024. The regions covered in the sarcoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Sarcoma drugs are pharmaceuticals designed for the treatment of sarcoma, a type of cancer that originates in connective tissues such as fat, muscle, blood vessels, nerves, and bones. These drugs are specifically formulated to target abnormal cells, either by directly inducing their death or by inhibiting their growth and multiplication.
The primary treatment modalities for sarcoma drugs include chemotherapy and targeted therapy. Chemotherapy, a widely employed cancer treatment, utilizes drugs to combat cancer cells. The range of disease indications for sarcoma drugs encompasses malignant bone tumors and soft tissue sarcoma, with distribution facilitated through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other relevant outlets.
The sarcoma drugs market research report is one of a series of new reports that provides sarcoma drugs market statistics, including sarcoma drugs industry global market size, regional shares, competitors with a sarcoma drugs market share, detailed sarcoma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoma drugs industry. This sarcoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sarcoma drug market consists of sales of atezolizumab, cosmegen, dactinomycin, doxorubicin hydrochloride, eribulin mesylate, fyarro, and gleevec. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Sarcoma Drugs Market Characteristics3. Sarcoma Drugs Market Trends and Strategies4. Sarcoma Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Sarcoma Drugs Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Sarcoma Drugs Market34. Recent Developments in the Sarcoma Drugs Market
5. Global Sarcoma Drugs Growth Analysis and Strategic Analysis Framework
6. Sarcoma Drugs Market Segmentation
7. Sarcoma Drugs Market Regional and Country Analysis
8. Asia-Pacific Sarcoma Drugs Market
9. China Sarcoma Drugs Market
10. India Sarcoma Drugs Market
11. Japan Sarcoma Drugs Market
12. Australia Sarcoma Drugs Market
13. Indonesia Sarcoma Drugs Market
14. South Korea Sarcoma Drugs Market
15. Western Europe Sarcoma Drugs Market
16. UK Sarcoma Drugs Market
17. Germany Sarcoma Drugs Market
18. France Sarcoma Drugs Market
19. Italy Sarcoma Drugs Market
20. Spain Sarcoma Drugs Market
21. Eastern Europe Sarcoma Drugs Market
22. Russia Sarcoma Drugs Market
23. North America Sarcoma Drugs Market
24. USA Sarcoma Drugs Market
25. Canada Sarcoma Drugs Market
26. South America Sarcoma Drugs Market
27. Brazil Sarcoma Drugs Market
28. Middle East Sarcoma Drugs Market
29. Africa Sarcoma Drugs Market
30. Sarcoma Drugs Market Competitive Landscape and Company Profiles
31. Sarcoma Drugs Market Other Major and Innovative Companies
35. Sarcoma Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Sarcoma Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on sarcoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sarcoma drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcoma drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Chemotherapy; Targeted Therapy2) By Disease Indication: Malignant Bone Tumors; Soft Tissue Sarcomaz
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Chemotherapy: Anthracyclines; Alkylating Agents; Antimetabolites; Other Chemotherapeutic Agents2) By Targeted Therapy: Tyrosine Kinase Inhibitors; MTOR Inhibitors; Monoclonal Antibodies; Other Targeted Therapies
Key Companies Mentioned: Amgen Inc.; Bayer AG; Eisai Co. Ltd.; Eli Lilly and Company; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Amgen Inc.
- Bayer AG
- Eisai Co. Ltd.
- Eli Lilly and Company
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Novartis AG
- Pfizer Inc.
- AgonOX Inc.
- Daiichi Sankyo Company Limited
- Merck & Co. Inc.
- AbbVie Inc.
- Amneal Pharmaceuticals LLC
- Pharma Mar SA
- Bristol-Myers Squibb Company
- Fresenius Kabi AG
- Ipsen SA
- Radiopharm Theranostics
- Akeso Biopharma
- AstraZeneca plc
- BeiGene Ltd.
- Bausch Health Companies Inc.
- Shenzhen Chipscreen Biosciences Co. Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Monopar Therapeutics Inc.
- Incyte Corporation
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Roche Holding AG
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | February 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 1.49 Billion |
Forecasted Market Value ( USD | $ 2.18 Billion |
Compound Annual Growth Rate | 9.9% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |